Slide 1: Optomed Q1 2024
Optomed Q1 2024 10th May 2024 Juho Himberg, CEO Sakari Knuutti, CFO
Slide 2: Highlights
Highlights 1. 2. 3. Optomed Aurora with Satisfactory New developments AEYE-DS AI has Q1 results in China successfully received FDA clearance
Slide 3: FDA Clearance
FDA Clearance • The first handheld device+AI to receive FDA clearance • Two large-scale prospective phase-III studies, in which the solution demonstrated best-in-class efficacy and imageability • 92% - 93% sensitivity • 89% - 94% specificity • 99+% imageability • Only a single image per eye
Slide 4: New Business Model
New Business Model FDA CLEARANCE ENABLES SIGNIFICANT RECURRING REVENUE OPPORTUNITY IN THE US Complete Solution Recurring Revenue Model Customer Benefits Newly established From product sales to Solution leased, reimbursement complete screening No initial investments not sold – enables code CPT 92229
Slide 5: Q1-2024 Key Figures
Q1-2024 Key Figures OUR TOPLINE DECLINED SLIGHTLY DUE TO QUIET QUARTER IN THE SOFTWARE SEGMENT Q1/2024 Q1/2023 Change Revenue 3,327 3,478 -4.4% Gross profit 2,213 2,476 -10.6% Gross margin 66.5% 71.2% -47pps Adjusted EBITDA -648 -513 -26.3% Adjusted EBITDA margin -19.5% -14.8% -47pps Net profit / lo
Slide 6: Segment highlights
Segment highlights OPT@MED
Slide 7: Devices Segment Q1-2024
Devices Segment Q1-2024 STABLE QUARTER FROM THE DEVICES SEGMENT Q1/2024 Q1/2023 Change Discussions with a prominent eye 1. hospital and private equity fund to establish a joint venture for eye Revenue 890 888 0.1% screening services Gross profit 516 559 -7.6% Gross margin was 58.0 (62.9) percent 2.
Slide 8: Software Segment Q1-2024
Software Segment Q1-2024 SOFTWARE REVENUE DECLINED SLIGHTLY AGAINST STRONG COMPARISON FIGURES Q1/2024 Q1/2023 Change Revenue and EBITDA declined vs 1. very strong comparison period figures when the growth was over 20 Revenue 2,437 2,590 -5.9 % percent Gross profit 1,697 1,917 -11.5 % After the revie
Slide 9: Cash Flow Q1-2024
Cash Flow Q1-2024 CASHFLOW WAS STABLE Q1 2024 Q1 2023 Loss for the financial year -1,090 -1,157 Cash flows before change • Net cash from operating in net working capital -596 -471 activities was EUR -0.52 million Change in net working capital 127 58 • The cash position was EUR 5.7 Cash flows before
Slide 10: Summary
Summary • FDA clearance obtained • The Finnish non-medical deal software contract secured and continues • Joint venture possibility in China • We are well positioned for the next phase of growth
Slide 11: Appendix
Appendix OPT@MED
Slide 12: Balance Sheet
Balance Sheet 31 March 2024 31 March 2023 • Equity ratio of 69.5 (64.7) ASSETS percent Goodwill 4,256 4,256 Development costs 7,996 6,849 Other intangible assets 1,680 1,991 • Total borrowings of EUR 3.1 Total intangible assets 13,932 13,096 (5.0) million Total tangible assets 652 793 Total non-curr